# ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Canonical URL: https://biopharmsignal.com/news/ALXO/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules-b37a2f05
Ticker: ALXO
Company: ALX Oncology
Source: ALX Oncology
Published: 2026-06-30 20:40 EST
Original Source URL: https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-reports-inducement-grant-permitted-nasdaq-listing-1
## Summary

SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the Compensation Committee of

## Article Body
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the Compensation Committee of
## Recent Company News
- 2026-06-30 20:40 EST — [ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules](https://biopharmsignal.com/news/ALXO/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules-b37a2f05) — Source: ALX Oncology
- 2026-06-30 12:00 EST — [ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel](https://biopharmsignal.com/news/ALXO/alx-oncology-appoints-scott-garland-as-chairman-of-the-board-and-michael-listgar-e952538a) — Source: ALX Oncology
- 2026-06-25 13:46 EST — [ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York](https://biopharmsignal.com/news/ALXO/alx-oncology-to-present-at-the-2026-jefferies-global-healthcare-conference-in-new-york) — Source: ALX Oncology
- 2026-06-25 13:46 EST — [ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ALXO/alx-oncology-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: ALX Oncology
- 2026-06-25 13:46 EST — [ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression](https://biopharmsignal.com/news/ALXO/alx-oncology-s-evorpacept-in-combination-with-zanidatamab-generates-promising-durable-response-in-patients-with-advanced-her2-positive-breast-cancer-and-high-cd47-expression) — Source: ALX Oncology
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)